• Home
  • Pharmacology
  • Biologics to Treat Substance Use Disorders: Vaccines, by Ivan D. Montoya

Biologics to Treat Substance Use Disorders: Vaccines, by Ivan D. Montoya

By Ivan D. Montoya

This booklet is a systematic compendium documenting the cutting-edge within the discovery and improvement of vaccines, monoclonal antibodies, and enzymes for the therapy of Substance Use issues (SUDs). The ebook supplies exact attention to a couple of the main innovative themes in dependancy medication, together with vaccines for nicotine, cocaine, heroin, and methamphetamine dependence; monoclonal antibodies opposed to cocaine, methamphetamine, and phencyclidine; and the enzymes butyrylcholinesterase and cocaine esterase. furthermore, the textual content covers a variety of new concepts designed to optimize the advance and efficacy of biologics. not like the other source, this e-book experiences how biologics supply interesting new healing possibilities for varied psychiatric stipulations.

Written via specialists within the box, Biologics to regard Substance Use problems is as an authoritative reference for psychiatrists, psychologists, and all different doctors operating with sufferers being affected by Substance Use Disorders.

Show description

Read Online or Download Biologics to Treat Substance Use Disorders: Vaccines, Monoclonal Antibodies, and Enzymes PDF

Similar pharmacology books

Phytopharmaceuticals in Cancer Chemoprevention

This publication specializes in the function of common supplementations in melanoma prevention and remedy. the 1st part covers melanoma epidemiology, melanoma facts and present remedies and strength toxicities concerned with present melanoma medicines. the second one part discusses the pathophysiology of melanoma together with mechanistic and molecular points of melanoma biology, etiology of breast melanoma, lung melanoma, prostate melanoma, tobacco and melanoma, gastrointestinal tract cancers and diverse chance elements regarding weight problems, workout and getting older.

The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services, and Outcome

Legislators, reporters and anxious voters often, while think about­ ing what to do concerning the plague of heroin dependancy in huge towns, ask an noticeable query: "Is methadone therapy potent? " this query is a serious one given that upkeep with methadone is at the present the single prac­ tical replacement to leaving tens of millions (in long island urban, thousands) of untreated addicts at the streets.

Extra resources for Biologics to Treat Substance Use Disorders: Vaccines, Monoclonal Antibodies, and Enzymes

Example text

Unfortunately, one of the main attributes not characterized were the nicotine affinities of nic · IgG due to the rapid wind-down of Nabi Biopharmaceuticals as a result of the phase III failures. Eliciting high-affinity nic · IgG is currently viewed as one of the most important aspects driving functional efficacy and is being actively targeted in the development of second generation of nicotine conjugate vaccines (McCluskie et al. 2013a, b). 3 describes a post hoc, pooled, completer analysis of both NicVAX phase III studies (NCT00836199 and NCT01102114) hypothesis generation of the putative threshold level of nic · IgG needed to support long-term abstinence.

1974;252:808–10. Cahill K, Stead L, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2012;4:CD006103. Carrera M, et al. Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorg Med Chem. 2004;12:563–70. CDC. Smoking & Tobacco Use: Fast Facts. [Online]. 2015. htm#cost. Accessed 4 July 2015. Cerny E, et al. Preclinical development of a vaccine ‘against smoking’. Onkologie. 2002;25(5):406–11. Cornuz J, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial.

Cfm. Accessed 5 July 2015. Pentel P, LeSage M. New directions in nicotine vaccine design and use. Adv Pharmacol. 2014;69:553–80. Pentel PR, et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav. 2000;65(1):191–8. Pittet L, et al. Development and preclinical evaluation of SEL-068, a novel targeted Synthetic Vaccine Particle (tSVP™) for smoking cessation and relapse prevention that generates high titers of antibodies against nicotine.

Download PDF sample

Rated 4.98 of 5 – based on 18 votes